Microdosing LSD analogues means taking tiny, sub-perceptual amounts of tweaked LSD that the body turns back into LSD. Hoped-for mood, focus, and creativity gains mostly fade once expectation is accounted for, while focus may slightly worsen. Downsides include raised blood pressure, anxiety, poor sleep, an unregulated supply, and unknown long-term safety. (Full Review)

Protocol

Dose

5–20 µg LSD-equivalent

Sub-perceptual, ~one-tenth of a recreational dose; trials titrate within roughly 6–20 µg

Schedule

Intermittent, non-daily

Fadiman (dose, two days off) or every-other-day patterns; 4–8 week block, then a break

Timing

Morning, single dose

Taken once per dosing day, not split; morning dosing avoids sleep disruption

Time to effect

Acute mood/alertness

Same day, 1–3 hours

Felt as the analogue converts to LSD

Claimed cumulative benefit

Over weeks

Described over weeks of an intermittent schedule; durable effects not confirmed

Active half-life

3–6 hours

Regenerated LSD clears well before night; analogue itself hydrolyzed rapidly

Benefits

Medium: Acute, short-lived mood elevation on dosing days

Low: Self-reported wellbeing, focus, and creativity in observational cohorts; reduced anxiety and depression symptoms

Speculative: Enhanced neuroplasticity and long-term cognitive or longevity benefit; cognitive enhancement

Contraindications

Lithium

MAOIs (e.g., phenelzine, tranylcypromine)

Personal or family history of psychotic or bipolar spectrum disorders

Significant cardiovascular disease or uncontrolled hypertension (≥160/100 mmHg)

Known cardiac valvulopathy

Pregnancy (any trimester) or breastfeeding

Key Interactions

SSRIs and SNRIs (e.g., fluoxetine, sertraline, venlafaxine)

Strong CYP2D6 or CYP1A2 inhibitors (e.g., bupropion, fluvoxamine)

Serotonergic OTC agents (dextromethorphan, St. John's Wort)

Serotonergic supplements (5-HTP, L-tryptophan, SAMe)

Stimulant supplements (high-dose caffeine, yohimbine)

Other psychedelics or recreational stimulants

Risk & Side Effects

High: Product impurity, mislabeling, and dosing uncertainty from unregulated supply; acute cardiovascular and sympathetic effects

Medium: Anxiety, jitteriness, and acute psychological discomfort; impaired cognitive control

Low: Sleep disruption; headache, nausea, and transient physical complaints

Speculative: Long-term and chronic-dosing harms; precipitation or worsening of psychosis in vulnerable individuals

Monitoring

Marker	Target	Why
Blood pressure	<120/80 mmHg	LSD raises blood pressure; identifies cardiovascular risk
Resting heart rate	50–70 bpm	LSD raises heart rate; flags sympathetic load
Lipid and metabolic panel	Standard optimal ranges	General cardiovascular context for longevity users

Cadence: Blood pressure and heart rate at baseline, again at ~1–2 weeks after starting a cycle, every few weeks during a dosing block, and reassessed before any subsequent cycle

Qualitative Assessment

Personal/family psychotic or bipolar history screen (no history)
Sleep quality and time to fall asleep
Daytime mood and emotional stability
Subjective focus, creativity, and motivation
Anxiety or jitteriness levels on and off dosing days
Overall sense of wellbeing across the dosing block

Microdosing LSD Analogues for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment